Aktis Oncology (NASDAQ:AKTS) Director Sells $119,263.36 in Stock

Aktis Oncology (NASDAQ:AKTS) Director Ken Herrmann sold 4,856 shares of the company’s stock in a transaction on Monday, July 20th. The stock was sold at an average price of $24.56, for a total transaction of $119,263.36. Following the completion of the transaction, the director owned 3,506 shares of the company’s stock, valued at $86,107.36. This trade represents a 58.07% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Aktis Oncology Trading Up 2.7%

Shares of AKTS opened at $23.00 on Friday. The firm’s 50-day moving average price is $24.22 and its 200-day moving average price is $20.94. The firm has a market capitalization of $1.23 billion and a price-to-earnings ratio of -60.53. Aktis Oncology has a 1-year low of $14.72 and a 1-year high of $34.19.

Aktis Oncology (NASDAQ:AKTS) last announced its quarterly earnings results on Monday, May 11th. The technology company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.01). The company had revenue of $3.23 million for the quarter, compared to the consensus estimate of $2.23 million. On average, research analysts forecast that Aktis Oncology will post -1.64 EPS for the current fiscal year.

Wall Street Analyst Weigh In

AKTS has been the topic of several recent research reports. William Blair began coverage on Aktis Oncology in a research note on Wednesday, April 29th. They issued an “outperform” rating on the stock. Raymond James Financial started coverage on shares of Aktis Oncology in a research report on Monday, June 15th. They issued a “strong-buy” rating and a $40.00 target price on the stock. HC Wainwright lifted their price target on shares of Aktis Oncology from $33.00 to $35.00 and gave the company a “buy” rating in a research report on Tuesday, June 2nd. JPMorgan Chase & Co. boosted their price objective on shares of Aktis Oncology from $30.00 to $33.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 14th. Finally, Weiss Ratings upgraded shares of Aktis Oncology from a “sell (d)” rating to a “sell (d+)” rating in a report on Tuesday, June 23rd. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Aktis Oncology presently has an average rating of “Moderate Buy” and an average target price of $34.60.

Aktis Oncology Company Profile

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.